Indeed, the application of anti‐PD‐L1/PD‐1 and anti‐CTLA‐4 for metastatic melanoma and lung cancer are now included in the National Comprehensive Cancer Network (NCCN) guidelines.9 This evidence concerns the gene CD274 and metastatic melanoma.